May 28, 2025

Kennedy Proposes NIH Publishing Ban

"We're probably going to stop publishing in The Lancet, New England Journal of Medicine, JAMA, and those other journals because they're all corrupt."

Conexiant

May 28, 2025

Low Neighborhood SES Linked to Higher HS Risk: Study 

A large cross-sectional study of over 65,000 dermatology patients found that individuals living in lower socioeconomic neighborhoods had significantly higher odds of receiving a new diagnosis of hidradenitis suppurativa, with risk decreasing across increasing SES levels.

Conexiant

May 27, 2025

New FDA approved Biosimilar Targets IL-12/23

The FDA has approved Starjemza, a ustekinumab biosimilar, for multiple inflammatory conditions.

Conexiant

May 22, 2025

New FDA-Approved Topical Foam for Scalp Psoriasis

The FDA has approved roflumilast (ZORYVE) foam 0.3% for once-daily treatment of plaque psoriasis in patients aged 12 and older, including hard-to-treat scalp and body areas..

Conexiant

May 22, 2025

Voices on the Go: Top Podcasts for Physicians

Physicians are tuning to podcasts that combine clinical insight, career development, and storytelling.

Conexiant

May 14, 2025

Once-Daily Pill Helps Quell Eczema in Phase 3

Overall, safety findings were consistent with those of other approved JAK1 inhibitors.

Conexiant

May 09, 2025

Psoriasis: Icotrokinra Shows Promise in Late-Stage Trial

Icotrokinra is designed to block a protein, IL-23, involved in inflammatory responses.

Reuters

May 05, 2025

Ustekinumab Biosimilar Receives Interchangeability Approval

Selarsdi (ustekinumab-aekn) was approved by the FDA as an interchangeable biosimilar to Stelara (ustekinumab) for all approved indications, including psoriasis, psoriatic arthritis, Crohn’s disease, and ulcerative colitis.

Conexiant

April 30, 2024

Novel Gene Variants May Be Predisposing Factor for Generalized Pustular Psoriasis

Researchers may have uncovered genetic factors linked to the development of generalized pustular psoriasis.

Conexiant